Company

Protheragen, a New York-based company established in 2005, is committed to inventing and developing novel therapeutic drugs for the treatment of cancer and CNS diseases. Over the past several years, Protheragen has developed novel technologies and designed protein drug candidates to fight oncology and CNS diseases. We have developed proprietary technology platforms including:

Technology for protein drug crossing through Blood Brain Barrier (BBB)

Next generation therapeutic antibody